DOI: 10.1055/s-00000059

Pneumologie

LinksClose Window

References

Karimi-Shah B.
Esbriet (pirfenidone) 2403 mg/day to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (Clinical Briefing Document).

In: Seymour S, ed.
FDA Briefing Information for the March 9, 2010 Meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC). NDA 22-535.

Washington, D.C.: US Food and Drug Administration; Available from:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf [accessed 2010 May 10]

Download Bibliographical Data

We do not assume any responsibility for the contents of the web pages of other providers.